Condition: Endometrial Cancer · Sponsor: Iovance Biotherapeutics, Inc.
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
This description comes directly from the study's public registry record.
Iovance Biotherapeutics Study Team · 1-844-845-4682 · Clinical.Inquiries@iovance.com
Always discuss trial participation with your own doctor first.
| Honor Health | Phoenix, Arizona, United States | Recruiting |
| University of Southern California | Los Angeles, California, United States | Recruiting |
| Orlando Health | Orlando, Florida, United States | Recruiting |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | Tampa, Florida, United States | Recruiting |
| Augusta University | Augusta, Georgia, United States | Recruiting |
| UofL Health - Brown Cancer Center | Louisville, Kentucky, United States | Recruiting |
| Barbara Ann Karmanos Cancer Hospital | Detroit, Michigan, United States | Recruiting |
| Roswell Park Cancer Institute | Buffalo, New York, United States | Recruiting |
| University of Oklahoma | Oklahoma City, Oklahoma, United States | Recruiting |
| Allegheny Health | Pittsburgh, Pennsylvania, United States | Recruiting |
| Avera Medical Group Oncology | Sioux Falls, South Dakota, United States | Recruiting |
| MD Anderson Cancer Center - U of Texas | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06481592